AKT1 and type 2 diabetes mellitus: Network pharmacology via PharmMapper indicates YQP modulates PI3K/Akt and MAPK pathways, improving lipid metabolism, OS, and inflammation in T2DM rats, suggesting a potential treatment mechanism [179].